title: HIV-Associated Lung Cancer.
abstract: Lung cancer (LC) is one of the most common non-AIDS (acquired immune deficiency syndrome)-defining malignancies. It occurs more frequently in persons living with human immunodeficiency virus (PLWHIV) than in the HIV-negative population. Compared to their HIV-negative counterparts, patients are usually younger and diagnosed at more advanced stages. The pathogenesis of LC in PLWHIV is not fully understood, but immunosuppression in combination with chronic infection and the oncogenic effects of smoking and HIV itself all seem to play a role. Currently, no established preventive screening is available, making smoking cessation the most promising preventive measure. Treatment protocols and standards are the same as for the general population. Notably, immuno-oncology will also become standard of care in a significant subset of HIV-infected patients with LC. As drug interactions and hematological toxicity must be taken into account, a multidisciplinary approach should include a physician experienced in the treatment of HIV. Only limited data is available on novel targeted therapies and checkpoint inhibitors in the setting of HIV.
authors.forename: Til R
authors.initials: TR
authors.lastname: Kiderlen
authors.forename: Jan
authors.initials: J
authors.lastname: Siehl
authors.forename: Marcus
authors.initials: M
authors.lastname: Hentrich
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000379:methods / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D008495:Medical Oncology / Q000592:standards; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000970:Antineoplastic Agents